217 related articles for article (PubMed ID: 11707862)
21. Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Paschal BR
Leuk Lymphoma; 2003 Apr; 44(4):731-3. PubMed ID: 12769354
[TBL] [Abstract][Full Text] [Related]
22. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
23. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
Turturro F
Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
[TBL] [Abstract][Full Text] [Related]
24. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
25. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
[TBL] [Abstract][Full Text] [Related]
26. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
27. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
30. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
Kerl K; Prins C; Cerroni L; French LE
Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
[TBL] [Abstract][Full Text] [Related]
31. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
32. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
[TBL] [Abstract][Full Text] [Related]
33. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.
Martin A; Gutierrez E; Muglia J; McDonald CJ; Guzzo C; Gottlieb A; Pappert A; Garland WT; Bagel J; Bacha P
J Am Acad Dermatol; 2001 Dec; 45(6):871-81. PubMed ID: 11712032
[TBL] [Abstract][Full Text] [Related]
34. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.
Foss FM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S27-31. PubMed ID: 11707860
[TBL] [Abstract][Full Text] [Related]
35. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
Foss FM; Waldmann TA
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
[TBL] [Abstract][Full Text] [Related]
37. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
[TBL] [Abstract][Full Text] [Related]
38. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
[TBL] [Abstract][Full Text] [Related]
39. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Gorgun G; Foss F
Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
